FOR IMMEDIATE RELEASE
Contact: Murray Penner
October 28, 2013, Washington, DC – The ADAP Crisis Task Force (Task Force) announced today that it has reached agreement with Bristol-Myers Squibb (BMS) and Boehringer Ingelheim (BI) to extend voluntary discounts/rebates and price freezes to all state AIDS Drug Assistance Programs (ADAPs). The continuation of existing agreements beyond 2013 will provide stability to ADAPs as they continue to navigate the uncharted terrain of a reformed health system as a result of implementation of the Affordable Care Act (ACA) and continued fiscal challenges at both the state and federal level.
The Task Force, convened by the National Alliance of State and Territorial AIDS Directors (NASTAD), previously secured continuation through 2014 of existing agreements for voluntary discounts and rebates from AbbVie, Gilead Sciences, Janssen Therapeutics, Merck and ViiV Healthcare. Many of these agreements also provide continued price freezes for ADAPs for varying lengths of time into 2014 and 2015. Continue reading
By Amy Killelea, Associate Director, Health Care Access, NASTAD
After a three and a half year wait – and several near-death experiences along the way – open enrollment under the Affordable Care Act (ACA) is finally here. On October 1st, 2013 the Marketplaces officially open for business, and millions of people will begin to apply for new public and private insurance coverage options. At this point, we all know the incredible opportunities to expand HIV and viral hepatitis prevention, care, and treatment that are at stake. Now is where the rubber meets the road as federal, state, and local advocates, providers, and programs roll up their sleeves and prepare for full implementation. Below are four action items the HIV and viral hepatitis community should be focusing on as we leap into open enrollment and beyond: Continue reading
By Ann Lefert, National Alliance of State and Territorial AIDS Directors and Bill McColl, AIDS United, Co-Chairs of the Ryan White Work Group, Federal AIDS Policy Partnership
As Co-Chairs of the Ryan White Work Group, we wanted to provide you with an update on the Ryan White Program. As you know, the current authorization ends on September 30, 2013. However, there is no “sunset” provision in the legislation. Therefore even if Congress does not take action, the Ryan White Program will remain a part of the law allowing funding to continue to be appropriated through the annual congressional appropriations process. Continue reading
FOR IMMEDIATE RELEASE
Contact: Meico Whitlock
August 26, 2013, Washington, DC – The ADAP Crisis Task Force (ACTF) has reached a new pricing agreement with ViiV Healthcare for AIDS Drug Assistance Programs (ADAPs) for Tivicay® (dolutegravir) for the treatment of HIV-1 infected individuals. The agreed-upon ADAP direct purchase price for Tivicay®, negotiated between the ACTF and ViiV, is substantially lower than the wholesale acquisition cost (WAC), reflecting voluntary discounts that are also significantly below the mandated 340B pricing of the medication.